Introduction
AD) dementia, amnestic mild cognitive impairment, AD dementia, MCI, Alzheimer’s disease
BRAIN ATROPHY, DISEASE
Donepezil is an acetylcholinesterase inhibitor (AChE-I) approved and standard-of-care for the symptomatic treatment of patients with Alzheimer’s disease (AD) dementia. Diverse clinical trials have demonstrated that donepezil has moderate effects on cognitive performance at different clinical symptomatic stages of AD [Notwithstanding this cross-disciplinary evidence, clinical trials of donepezil in prodromal stages of AD have provided inconsistent data so far [The study of biological subtypes in AD has opened a window to unravel the disease heterogeneity [Conceptual framework of AD subtyping dimensions. In this study, we selected a global brain atrophy index (BV/CSF index; [The main objective of this study is to investigate the response to donepezil in different MRI subtypes of individuals with amnestic mild cognitive impairment (MCI), which is considered the prodromal stage of AD dementia [